Tags

Type your tag names separated by a space and hit enter

Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin.
Int J Antimicrob Agents. 2011 Jun; 37(6):547-9.IJ

Abstract

Burkholderia pseudomallei, the causative agent of melioidosis, continues to present therapeutic challenges in endemic areas. A number of clinical issues have prompted consideration of alternative antimicrobial therapies. These include stability in 24-h infusion pumps, broad-spectrum coverage in the empirical treatment of community-acquired pneumonia, cost, the need for effective oral agents and rare reports of emerging resistance. This study aimed to examine the in vitro susceptibility of B. pseudomallei to four new antimicrobial agents, namely moxifloxacin, tigecycline, ertapenem and doripenem. A total of 100 clinical isolates were tested by Etest and disk diffusion. As there are no interpretative standards for these antimicrobials, MIC(90) values (minimum inhibitory concentrations for 90% of the isolates) were compared with those for meropenem. MIC values for each agent were correlated with zone of inhibition diameters. MICs for doripenem were broadly similar to those for meropenem, with a MIC(90) of 1.5 μg/mL (range 0.38-4 μg/mL). There was good correlation (r=-0.71; P<0.001) between the MIC and disk diffusion for doripenem. Ertapenem, tigecycline and moxifloxacin had limited in vitro activity in this study, although no interpretative criteria exist for these agents. Further in vitro, animal and clinical studies are suggested to validate the efficacy of doripenem in the management of melioidosis.

Authors+Show Affiliations

Pathology Queensland, Townsville Hospital, 100 Angus Smith Drive, Douglas, Queensland 4814, Australia. padstock@hotmail.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

21481571

Citation

Harris, Patrick, et al. "Comparative in Vitro Susceptibility of Burkholderia Pseudomallei to Doripenem, Ertapenem, Tigecycline and Moxifloxacin." International Journal of Antimicrobial Agents, vol. 37, no. 6, 2011, pp. 547-9.
Harris P, Engler C, Norton R. Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin. Int J Antimicrob Agents. 2011;37(6):547-9.
Harris, P., Engler, C., & Norton, R. (2011). Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin. International Journal of Antimicrobial Agents, 37(6), 547-9. https://doi.org/10.1016/j.ijantimicag.2011.02.001
Harris P, Engler C, Norton R. Comparative in Vitro Susceptibility of Burkholderia Pseudomallei to Doripenem, Ertapenem, Tigecycline and Moxifloxacin. Int J Antimicrob Agents. 2011;37(6):547-9. PubMed PMID: 21481571.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin. AU - Harris,Patrick, AU - Engler,Cathy, AU - Norton,Robert, Y1 - 2011/04/09/ PY - 2010/12/22/received PY - 2011/01/30/revised PY - 2011/02/01/accepted PY - 2011/4/13/entrez PY - 2011/4/13/pubmed PY - 2011/8/4/medline SP - 547 EP - 9 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 37 IS - 6 N2 - Burkholderia pseudomallei, the causative agent of melioidosis, continues to present therapeutic challenges in endemic areas. A number of clinical issues have prompted consideration of alternative antimicrobial therapies. These include stability in 24-h infusion pumps, broad-spectrum coverage in the empirical treatment of community-acquired pneumonia, cost, the need for effective oral agents and rare reports of emerging resistance. This study aimed to examine the in vitro susceptibility of B. pseudomallei to four new antimicrobial agents, namely moxifloxacin, tigecycline, ertapenem and doripenem. A total of 100 clinical isolates were tested by Etest and disk diffusion. As there are no interpretative standards for these antimicrobials, MIC(90) values (minimum inhibitory concentrations for 90% of the isolates) were compared with those for meropenem. MIC values for each agent were correlated with zone of inhibition diameters. MICs for doripenem were broadly similar to those for meropenem, with a MIC(90) of 1.5 μg/mL (range 0.38-4 μg/mL). There was good correlation (r=-0.71; P<0.001) between the MIC and disk diffusion for doripenem. Ertapenem, tigecycline and moxifloxacin had limited in vitro activity in this study, although no interpretative criteria exist for these agents. Further in vitro, animal and clinical studies are suggested to validate the efficacy of doripenem in the management of melioidosis. SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/21481571/Comparative_in_vitro_susceptibility_of_Burkholderia_pseudomallei_to_doripenem_ertapenem_tigecycline_and_moxifloxacin_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(11)00079-3 DB - PRIME DP - Unbound Medicine ER -